Equities

SSY Group Ltd

SSY Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)3.81
  • Today's Change-0.03 / -0.78%
  • Shares traded8.46m
  • 1 Year change-12.21%
  • Beta0.5824
Data delayed at least 15 minutes, as of Sep 20 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in HKDIncome statement in HKDView more

Year on year SSY Group Ltd grew net income 17.44% from 1.12bn to 1.32bn despite relatively flat revenues.
Gross margin54.39%
Net profit margin21.30%
Operating margin26.21%
Return on assets11.54%
Return on equity20.08%
Return on investment14.88%
More ▼

Cash flow in HKDView more

In 2023, SSY Group Ltd did not generate a significant amount of cash. However, the company earned 925.75m from its operations for a Cash Flow Margin of 14.32%. In addition the company used 640.19m on investing activities and also paid 304.57m in financing cash flows.
Cash flow per share0.6151
Price/Cash flow per share6.23
Book value per share2.44
Tangible book value per share2.04
More ▼

Balance sheet in HKDView more

SSY Group Ltd has a Debt to Total Capital ratio of 32.31%, a higher figure than the previous year's 27.00%.
Current ratio2.63
Quick ratio2.06
Total debt/total equity0.4981
Total debt/total capital0.323
More ▼

Growth rates in HKD

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 21.43% and 17.69%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)2.74%
Div growth rate (5 year)13.56%
Payout ratio (TTM)39.13%
EPS growth(5 years)8.10
EPS (TTM) vs
TTM 1 year ago
14.99
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.